Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Publications

Matulonis, UA, Oza, AM, Secord, AA, Roman, LD, Blagden, SP, Banerjee, SN, Elkas, JC, Nemunaitis, JJ, Ghamande, SA, Fleming, GF, Markham, MJ, Hirte, HW, Provencher, DM, Basu, B, Kristeleit, RS, Naim, S, Hao, Y, Keer, HN, Azab, M, and Matei, D. "Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study." May 20, 2016.

Scholars@Duke

Foote, J, Liang, M, Secord, AA, Cohn, DE, and Havrilesky, LJ. "Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum sensitive ovarian cancer." May 20, 2016.

Full Text

Davidson, BA, Squatrito, R, Duska, LR, Havrilesky, LJ, Schwager, N, McCollum, M, Arapovic, S, and Secord, AA. "Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma." May 20, 2016.

Full Text

Secord, AA, Tritchler, D, Liu, Y, Starr, MD, Brady, JC, Lankes, HA, Hurwitz, H, Mannel, RS, Tewari, KS, O'Malley, DM, Gray, HJ, Bakkum-Gamez, JN, Fujiwara, K, Boente, M, Deng, W, Burger, RA, Birrer, MJ, and Nixon, AB. "Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatinpaclitaxel (CP) +/- bevacizumab (BEV). Results from GOG-0218." May 20, 2016.

Scholars@Duke

Ehrisman, JA, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Broadwater, G, Li, X, Havrilesky, LJ, and Hall, A. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-Grade Endometrial Cancer." February 2016.

Scholars@Duke

Davidson, BA, Foote, J, Brower, SL, Tian, C, Havrilesky, LJ, and Secord, AA. "Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis." Gynecologic oncology research and practice 3 (January 2016): 13-.

Full Text

Secord, AA, Hasselblad, V, Von Gruenigen, VE, Gehrig, PA, Modesitt, SC, Bae-Jump, V, and Havrilesky, LJ. "Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis." Gynecologic oncology 140, no. 1 (January 2016): 184-190. (Review)

Full Text

Gray, HJ, Benigno, B, Berek, J, Chang, J, Mason, J, Mileshkin, L, Mitchell, P, Moradi, M, Recio, FO, Michener, CM, Secord, AA, Tchabo, NE, Chan, JK, Young, J, Kohrt, H, Gargosky, SE, and Goh, JC. "Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial." Journal for immunotherapy of cancer 4 (January 2016): 34-.

Full Text

Gaillard, SL, Secord, AA, and Monk, B. "The role of immune checkpoint inhibition in the treatment of ovarian cancer." Gynecologic oncology research and practice 3 (January 2016): 11-. (Review)

Full Text

Fuh, KC, Secord, AA, Bevis, KS, Huh, W, ElNaggar, A, Blansit, K, Previs, R, Tillmanns, T, Kapp, DS, and Chan, JK. "Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients." Gynecologic oncology 139, no. 3 (December 2015): 413-418.

Full Text

Pages